Zacks Investment Research
13 Oct 2025, 19:50 UTC · 49w ago
Verdict
Headline leans bullish. We score PTGX +1.00.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares rose 30% following reports that J&J is interested in acquiring the company.
Near neutral — 92% of ticker scores this week are stronger
The potential acquisition is a strategic fit to offset declining Stelara sales, but the loss of patent exclusivity is a headwind.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Near neutral — 92% of ticker scores this week are stronger
The company is mentioned in a list of quotes but there is no news or sentiment provided.
More positive than 75% of relationship scores this week
[mutual] J&J holds exclusive worldwide rights to develop Protagonist Therapeutics' drug icotrokinra in phase II studies and beyond.
More positive than 75% of relationship scores this week
[mutual] Protagonist Therapeutics is developing the candidate rusfertide in partnership with Takeda Pharmaceuticals.
More positive than 14% of relationship scores this week
[a_to_b] J&J is reportedly interested in acquiring Protagonist Therapeutics and the companies are in ongoing discussions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
13h ago
+63.1%
Price agrees with the score
$141.86 vs $87.00 close before publication (Oct 10) · not market-adjusted
PTGX chart →
